BriaCell CEO Gives Corporate Overview, Plans for Future in Audio Interview with SmallCapVoice.com
21 avr. 2021 08h00 HE
|
Briacell Therapeutics Corp.
AUSTIN, Texas, April 21, 2021 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Bill Williams, M.D., President and CEO of BriaCell Therapeutics...
Buchanan, Luria, Mace, Sherrill, and Boyle Introduce FDA Modernization Act to End Mandatory Animal Testing, Lower Drug Prices
20 avr. 2021 11h15 HE
|
Animal Wellness Action
Washington, D.C., April 20, 2021 (GLOBE NEWSWIRE) -- Today, Animal Wellness Action, the Center for a Humane Economy, the Michelson Center for Public Policy, and other affiliated organizations...
Blackbriar Regulatory Services, LLC Partners with Beard Management Inc.
13 avr. 2021 09h30 HE
|
Blackbriar Regulatory Services
RICHMOND, Va., April 13, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Blackbriar Regulatory Services (BRS), a firm specializing in helping small to mid-sized domestic and international companies...
vTv Therapeutics Receives FDA Breakthrough Therapy Designation for TTP399 for the Treatment of Type 1 Diabetes
13 avr. 2021 07h30 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., April 13, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for...
Allarity Therapeutics Submits Premarket Approval Application to U.S. FDA for DRP® Companion Diagnostic for Dovitinib
02 avr. 2021 07h00 HE
|
Allarity Therapeutics A/S
- Submission precedes expected NDA filing for dovitinib in 2021 - Premarket Approval will allow U.S. marketing of DRP-Dovitinib as companion diagnostic to dovitinib Press release ...
Starton Therapeutics Completes Pre-IND Meeting with FDA: Clearing Path to Phase 1 Clinical Study for STAR-LLD Continuous Infusion
22 mars 2021 08h30 HE
|
Starton Therapeutics, Inc.
PARAMUS, N.J., March 22, 2021 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical stage biotechnology company with a continuous delivery platform of approved drugs...
Becerra Confirmation Boosts 22nd Century’s Position to Disrupt Tobacco Industry
19 mars 2021 13h00 HE
|
22nd Century Group, Inc
WILLIAMSVILLE, N.Y., March 19, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company focused on tobacco harm reduction, very low...
SweeGen’s Bestevia® Rebaudioside B Receives U.S. FDA GRAS No Objection Letter
15 mars 2021 14h25 HE
|
SweeGen, Inc.
Rancho Santa Margarita, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- Ready for use in creative food and beverage innovations, SweeGen’s Bestevia Rebaudioside B has received the GRAS (Generally...
22nd Century Group Receives Additional $3.7 Million from Cash Exercise of Outstanding Warrants
12 mars 2021 10h00 HE
|
22nd Century Group, Inc
WILLIAMSVILLE, N.Y., March 12, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company focused on tobacco harm reduction, very low...
22nd Century Group Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2020
11 mars 2021 07h00 HE
|
22nd Century Group, Inc
Key Business and Financial Highlights 22nd Century has a tremendous global commercial opportunity in the more than $800 billion markets across the tobacco and hemp/cannabis industry.Securing Modified...